검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | G-CSF |
Overview Company | Sandoz |
Overview Modality | ANTIBODY |
Overview Target | Hodgkin Lymphoma |
Overview Indication | Multiple Myeloma; Post-transplant MRD-guided Maintenance Therapy |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting RCC-associated minor histocompatibility antigen |
MoA Biomarker | biomarkers (e |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Safety and efficacy of Efbemalenograstim alfa for patients at risk for chemotherapy-induced neutropenia: A Systematic review and Meta-analysis.. Chemotherapy-induced neutropenia (CIN) and its severe complication, febrile neutropenia, remain major challenges in oncology. Although granulocyte colony-stimulating factors (GCSFs) have reduced the incidence of these complications, limitations related to… |
Clinical Primary efficacy | ORR 93% |
Clinical ORR | 93% |
Clinical Result source | ClinicalTrials.gov NCT03646123 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | G-CSF |
Overview Company | Sandoz |
Overview Modality | ANTIBODY |
Overview Target | Hodgkin Lymphoma |
Overview Indication | Multiple Myeloma; Post-transplant MRD-guided Maintenance Therapy |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting RCC-associated minor histocompatibility antigen |
MoA Biomarker | biomarkers (e |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Safety and efficacy of Efbemalenograstim alfa for patients at risk for chemotherapy-induced neutropenia: A Systematic review and Meta-analysis.. Chemotherapy-induced neutropenia (CIN) and its severe complication, febrile neutropenia, remain major challenges in oncology. Although granulocyte colony-stimulating factors (GCSFs) have reduced the incidence of these complications, limitations related to… |
Clinical Primary efficacy | ORR 93% |
Clinical ORR | 93% |
Clinical Result source | ClinicalTrials.gov NCT03646123 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
추천 비교
추천 비교